Qualification of an enzyme-linked immunosorbent assay for quantification of anti-Vi IgG in human sera.
Vi
antibodies
enteric fever
enzyme - linked immunosorbent assay (ELISA)
human
typhoid
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
07
2024
accepted:
20
09
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Effective vaccines against
Identifiants
pubmed: 39478859
doi: 10.3389/fimmu.2024.1466869
pmc: PMC11521798
doi:
Substances chimiques
Immunoglobulin G
0
Antibodies, Bacterial
0
Polysaccharides, Bacterial
0
Typhoid-Paratyphoid Vaccines
0
capsular polysaccharide, Salmonella
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466869Informations de copyright
Copyright © 2024 Carducci, Massai, Lari, Semplici, Aruta, De Simone, Piu, Montomoli, Berlanda Scorza, Grappi, Iturriza-Gómara, Canals, Rondini and Rossi.
Déclaration de conflit d'intérêts
This work was sponsored by GlaxoSmithKline Biologicals SA. GSK Vaccines Institute for Global Health Srl is an affiliate of GlaxoSmithKline Biologicals SA. MC, LM, MS, DS, MI-G, FS, SR, RC and O.R. are employees of the GSK group of companies. FS, MI-G, RC, SR, MC, and OR report ownership of GSK shares/share options. EL, BS, PP, EM, SG are employees of Vismederi Srl. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission.